Trial Profile
A phase II clinical trial of CEN501 a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs CEN 501 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- 10 Jun 2022 According to an ABVC Biopharma media release, under the terms of the now terminated agreement, BioKey was to be paid dollar 3.0 million over a 3-year period to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements. ABVC and NeuCen had also agreed, subject to further negotiation, that ABVC would loan NeuCen dollar 1.0 million through a series of convertible debentures.
- 10 May 2022 New trial record
- 03 May 2022 According to an ABVC Biopharma media release, the BioKey, a wholly-owned subsidiary of the company entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements.